Invitae completed the acquisition of Diploid for $95m.

Invitae, a medical genetics company, completed the acquisition of Diploid, a privately held Belgian company that developed Moon, artificial intelligence software capable of diagnosing genetic disorders in minutes based on next-generation sequencing data and patient information, for $95m. "The addition of Diploid's software to Invitae's best-in-class variant interpretation platform will provide an immediate increase in throughput, improving the customer experience and lowering COGS for our exome offering, further extending the advantage of Invitae's platform to the benefit of clinicians and their patients. More importantly, this technology will help us accelerate progress toward the routine use of whole genome sequencing in addition to panel and exome testing, ultimately helping more patients get the diagnosis they need, sooner," Sean George, Invitae Co-Founder and CEO.